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Abstract	49 
In the autoimmune disease multiple sclerosis (MS) and its animal model Experimental 50 
Autoimmune Encephalomyelitis (EAE), expansion of pathogenic, myelin-specific Th1 cell 51 
populations drives active disease; selectively targeting this process may be the basis for a new 52 
therapeutic approach. Previous studies have hinted a role for protein arginine methylation in 53 
immune responses, including T cell-mediated autoimmunity and EAE. However, a conclusive 54 
role for the Protein Arginine Methyl Transferase (PRMT) enzymes that catalyze these reactions 55 
has been lacking.  PRMT5 is the main PRMT responsible for symmetric dimethylation of 56 
arginine residues of histones and other proteins. PRMT5 drives embryonic development and 57 
cancer, but its role in T cells, if any, has not been investigated. Here, we show that PRMT5 is an 58 
important modulator of CD4+ T cell expansion. PRMT5 was transiently up-regulated during 59 
maximal proliferation of both mouse and human memory Th cells. PRMT5 expression was 60 
regulated upstream by the NF-kB pathway, and it promoted IL-2 production and proliferation.  61 
Blocking PRMT5 with novel, highly selective small molecule PRMT5 inhibitors severely 62 
blunted memory Th expansion, with preferential suppression of Th1 over Th2 cells. In vivo, 63 
PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in 64 
Delayed Type Hypersensitivity (DTH) and clinical disease in Experimental Autoimmune 65 
Encephalomyelitis (EAE) mouse models. These data implicate PRMT5 in regulation of adaptive 66 
memory T helper cell responses and suggest PRMT5 inhibitors may be a novel therapeutic 67 




1. Introduction 71 
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system that 72 
affects 2 million young adults worldwide (1). MS is driven by myelin-reactive inflammatory T 73 
cells, resulting in axonal demyelination and disability (2). The reactivation and expansion of 74 
myelin-specific inflammatory T cells is associated with active MS disease, including relapses (3-75 
8). Drugs that suppress these processes may therefore prevent or curtail the spread of this 76 
devastating disease. 77 
MS is associated with both increased Th1 and Th17 inflammatory responses (9) and deficient 78 
Th2 and Treg responses (10). In particular, an imbalance between reciprocal Th1 and Th2 79 
responses has been reported as an important etiologic factor in MS. Several studies have shown 80 
that T cells from MS  patients favor the pro-inflammatory Th1 phenotype as opposed to a Th2 81 
phenotype (11-13). Furthermore, although myelin-reactive T cells are present in healthy 82 
individuals, MS patients have increased frequencies of myelin-specific T cells with an activated 83 
memory phenotype (14-16).   84 
Upon re-exposure to antigen, memory T cells multiply quickly, providing a large army of 85 
responding T cells. TCR stimulation results in the activation of several signaling pathways, 86 
including Notch, c-myc, NFAT, ERK, JNK, NF-kB and mTOR pathways (17). Nuclear 87 
translocation of NFAT, Oct, NF-kB and AP-1 transcription factors activate transcription of the 88 
pro-proliferative cyokine IL-2 (18). In addition, Notch and c-myc induce T cell proliferation 89 
(19), whereas the mTOR pathway is essential for glucose metabolism in proliferating T cells 90 
(20). Memory T cells transition quickly from a non-proliferative resting state to maximal 91 
proliferation 2-4 days after antigen exposure. This is followed by a return to a resting state 7-10 92 
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days later (21). Although this process is essential in the immune response against bacterial and 93 
other infections, memory T cell expansion in response to self-antigens can be harmful, resulting 94 
in excessive inflammation and autoimmunity.  95 
What role, if any, arginine methylation plays in this process remains vastly unexplored. 96 
However, previous studies provide some clues for further investigation. A role for methylation in 97 
physiologic immune responses was first suggested by the clinical signs of a debilitating 98 
immunodeficiency observed in adenosine deaminase (ADA)-deficient patients (22,	23). In 99 
ADA, the accumulation of adenosine and deoxyadenosine inhibits S-adenosyl methionine 100 
(SAM)-dependent methylation reactions (23,	24). In particular, TCR/CD28-mediated 101 
proliferation and cytokine production are inhibited in ADA deficient patients (22,	23). Similarly, 102 
global methyltransferase inhibitors have been shown to have strong immunosuppressive 103 
properties and abrogate T cell-mediated autoimmunity (25-28). Methylthioadenosine (MTA), a 104 
physiological methyl-donor substrate for methylation reactions, can also act as a methylation 105 
inhibitor when present at high concentrations (27). It has been recently shown that alterations in 106 
the tumor environment result in high tumoral MTA levels that inhibit protein arginine 107 
methylation and suppress anti-cancer human T cell responses. Accumulating evidence therefore 108 
hints that the T cell effects of global methyltransferase inhibition are due to inhibition of Protein 109 
Arginine Methyl Transferases (PRMT) (29,	30). However, conclusive evidence demonstrating 110 
that PRMT are responsible for T cell suppression, as well as a specific role for the main 111 
symmetric dimethylation enzyme PRMT5, has been lacking. 112 
PRMTs are a family of enzymes that catalyze arginine methylation of nucleosomal histones on 113 
chromatin and other proteins. Among PRMTs, type I PRMTs (PRMT1-4, 6 and 8) catalyze 114 
asymmetric dimethylation, while type II PRMTs (PRMT5 and 9) catalyze symmetric 115 
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dimethylation at the w-NH2 of arginine (31). Although PRMT9 can catalyze symmetric 116 
dimethylation of certain substrates, most SDM reactions of histones are catalyzed by PRMT5 117 
(32). PRMT7 was considered a type II PRMT until recently but has been reclassified as a 118 
monomethylating Type III PRMT (33). The modifications catalyzed by PRMTs play a crucial 119 
role in a variety of cellular processes, from differentiation to signaling and proliferation (34). 120 
Among PRMTs, PRMT5 appears to play a particularly relevant role in the regulation of cell 121 
death and malignant transformation processes in mouse and humans (35-38). Indeed, PRMT5 is 122 
up-regulated in various human lymphoid malignancies (39-41) and solid tumors (42-48) and 123 
promotes cancer cell proliferation and survival (38,	46,	49,	50). This has led to the development 124 
of selective PRMT5-inhibiting drugs such as CMP5 and EPZ015666 as a potential new therapy 125 
in cancer (43,	51,	52). While PRMT5 is clearly involved in tumor growth and survival, its role 126 
in T cell responses and its impact on autoimmunity are unknown. 127 
Here, we set out to investigate the role of PRMT5 activity in expansion of pathogenic Th1 cells 128 
that lead to MS. We found that PRMT5 transient up-regulation in response to TCR engagement 129 
in vitro is conserved in mouse and human memory Th1 and Th2 CD4+ T cells. PRMT5 up-130 
regulation in Th1 cells required NF-kB signaling, and inhibition of PRMT5 activity with 131 
PRMT5-selective inhibitors blunted IL-2 secretion and proliferative responses of memory Th 132 
cells. Interestingly, pathogenic Th1 cells were more sensitive to PRMT5 inhibition than benign 133 
Th2 cells, a desirable immunological profile for MS drugs. In vivo, treatment with the novel 134 
PRMT5 inhibitor HLCL65 suppressed antigen-specific T cell responses and inflammation in the 135 
DTH model of inflammation and EAE model of MS. This is the first evidence that PRMT5 plays 136 
an essential role in pathogenic Th1 cell responses. Further, we describe novel potent PRMT5 137 
selective inhibitors that may provide a novel therapeutic strategy for Th1-mediated inflammatory 138 
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autoimmune disease.	 	139 
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2. Materials and Methods. 140 
2.1. Mice.  141 
B10.PL (Jackson labs) and MBP TCR Tg mice (described by Dr. Goverman (53)) were bred in 142 
specific pathogen-free conditions at the OSU University Laboratory Animal Resources, under 143 
protocol # 2013A00000151. C57BL/6 and BALB/c mice were purchased from Taconic and 144 
Jackson laboratories, respectively. 145 
2.2. Reagents.  146 
PRMT5 inhibitor CMP5 was designed and synthesized at The Ohio State University as 147 
previously described (51). Briefly, the compound was designed to fit into the PRMT5 enzyme 148 
crystal structure, partially covering the binding pockets for both the methyl group donor, S-149 
adenosylmethionine (SAM), and the acceptor protein arginine group. Stock CMP5 was dissolved 150 
in dimethylsulfoxide (DMSO) vehicle at a concentration of 100mM and further diluted to 25µM 151 
in DMSO for in vitro assays. PRMT5 inhibitor HLCL65 was dissolved in DMSO vehicle at a 152 
concentration of 50mM and was further diluted for in vitro assays. Stock Bay 11-7082 was 153 
dissolved in DMSO vehicle at a concentration of 10 mM. Bay 11 was further diluted at least 154 
1:1000 for in vitro assays.  155 
2.3. HLCL65-binding interaction prediction.  156 
The crystal structure of human PRMT5:MEP50 complex (PDB ID: 4GQB) was used to predict 157 
the binding interaction of HLCL65 within the PRMT5 active site. The co-crystallized AdoMet 158 
analog (A9145C) and the histone H4 derived substrate peptide were deleted from the binding 159 
site. The small molecule ligand HLCL65 was prepared by Maestro (Schrödinger). Molecular 160 
docking was accomplished by Autodock4. The binding energy of the protein-ligand interaction 161 
in the shown binding mode was -13.14 kcal/mol. 162 
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2.4. Histone methyltransferase assays.  163 
Histone methylation was performed using 2 µg of HeLa S3 core histones in the presence or 164 
absence of 15 µl of affinity-purified human SWItch/Sucrose Non Fermentable (hSWI/SNF) 165 
associated Flag-tagged PRMT5 or Flag-tagged PRMT7, as described previously (54). Reaction 166 
mixtures were spotted on Whatman P-81 filter paper, washed five times with 10 ml of 0.1 mm 167 
sodium carbonate buffer (pH 9.0) to remove unincorporated [3H]AdoMet, and methylated 168 
peptides were detected by scintillation counting. 169 
2.5. Cells.  170 
Mouse Th1 and Th2 cell lines were generated from Myelin Basic Protein (MBP) Ac1-11-specific 171 
T cell receptor (TCR) transgenic mice (53). Naïve T cells were isolated from TCR transgenic 172 
splenocytes by magnetic bead sorting using the CD4+CD62L+ isolation kit (Miltenyi Biotech) 173 
and activated with MBPAc1-11 (0.5 µg/ml) presented in irradiated splenocytes in Th1 (IL-12 + 174 
IFN-γ, anti-IL-4) or Th2 (IL-4, anti-IL-12 and anti-IFN-γ) conditions for two rounds. Th cell 175 
lines are not transformed and were therefore maintained by stimulation with MBPAc1-11 and 176 
irradiated splenocytes in the presence of recombinant IL-2 every 7-10 days. T cells collected 7-177 
10 days after activation with MBPAc1-11 and irradiated splenocytes provided the resting Th cell 178 
condition. To avoid the presence of non-T cells in in vitro experiments, resting Th1 or Th2 cell 179 
lines were activated with anti-CD3/CD28 in the presence or absence of the PRMT5 inhibitors 180 
CMP5, HLCL65 or DMSO as vehicle control for various lengths of time indicated throughout 181 
the manuscript. Human Th1 and Th2 cells were generated by isolating CD4+ T cells with CD4+ 182 
T cell isolation kit (Stem Cell Technologies) from human whole blood leukocytes from normal 183 
donors and activating on anti-CD3/CD28 Dynabeads (ThermoScientific) in Th1 or Th2 184 
conditions (same as mouse) for 1 week. Th cells were then removed from the Dynabeads and 185 
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reactivated with plate bound anti-CD3 (1ug/ml for Th1, 5ug/ml for Th2) and soluble CD28 186 
(1ug/ml for Th1, 2ug/ml for Th2) for further experiments. Naïve CD4+ T cells were isolated with 187 
the mouse naïve CD4+ T cell isolation kit (Miltenyi) and activated with 5ug/ml coated anti-CD3 188 
and 2ug/ml soluble anti-CD28. CCMCL1 cell lines are a mantle cell lymphoma cell line, 189 
described previously (55).  190 
2.6. Western blot.  191 
Cells were lysed in Passive Lysis Buffer (Promega) or RIPA buffer (10mM Tris, 150mM NaCl, 192 
1% Triton X-100, 0.1% SDS, 1% deoxycholate) containing protease inhibitors and phosphatase 193 
inhibitors (Thermo Scientific). Protein concentrations were determined by Nanodrop 2000 or 194 
BCA assay (ThermoFisher).  Equal quantities of protein (5-10 µg) were separated on 10-14% 195 
SDS-PAGE gels, and transferred to nitrocellulose or PVDF membranes (Biorad, 162-0177).  196 
Membranes were incubated with rabbit anti-PRMT5 (Abcam Ab31751, 1:500) antibody, anti-197 
PRMT1 (CST 2449S), anti-PRMT7 (ab22110) or mouse anti-β-actin (Sigma, A1978 1:20000) 198 
antibody overnight at 4°C or for 3 hours at room temperature.  After incubation with HRP-199 
conjugated anti-rabbit (Sigma, A0545, 1:15000) or anti-mouse (Sigma, A9044 1:20000) 200 
antibody, Westerns were developed with SuperSignal West Pico Chemiluminescent Substrate 201 
(Thermo Scientific) and the luminescent signal was captured on film and developed on a Konica-202 
Minolta SRX-101A or digitally on a Fuji LAS-4000 Imaging System. After incubation with 203 
fluorescently labeled anti-rabbit or anti-mouse secondary antibodies (Odyssey LI-COR), Western 204 
blots were imaged with Odyssey CLx. The western blotting bands were analyzed by ImageJ 205 
(Bio-Arts, Co. Ltd., Fukuoka, Japan) or ImageStudio software.   206 
2.7. RNA isolation.  207 
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RNA was isolated with Trizol (Life Technologies) or the mirVana kit (Life Technologies) total 208 
RNA isolation protocol, according to manufacturer’s instructions, and stored at -800C until 209 
analysis. RNA concentration and quality was determined using NanoDrop 2000.   210 
2.8. Real-Time PCR.  211 
For Real-Time PCR, 300-1000 ng of RNA from profiled samples were cDNA transcribed using 212 
random primers and Superscript II (Applied Biosystems) and Taqman  Real-Time PCR was 213 
performed using mTbx21 (Mm00450960_m1) and mHPRT (Mm0044968_m1) primer sets (Life 214 
Technologies), according to manufacturer samples were cDNA transcribed using random 215 
primers and Superscript III (Applied Biosystems of similar amplification efficiency for test and 216 
control genes.) Initial denaturation step at 95°C for 10 minutes was followed by 40 cycles of 217 
denaturation at 95°C for 15 seconds and primer annealing/extension at 60°C for 60 seconds. 218 
Results were analyzed using the comparative Ct method. 219 
2.9. Cytokine ELISA.  220 
Cytokines were detected in supernatants at various points post-stimulation by a sandwich 221 
ELISA. Mouse IL-2 reagents were from BD, mouse IL-17 reagents were purchased from 222 
eBiosciences (Capture: 14-7175-85, Detection: 13-7177-85), human IL-2 reagents were 223 
purchased from Biolegend (Capture: 500302, Detection: 517605) and recombinant human IL-2 224 
was purchased from Miltenyi. ELISA was performed as previously described (12).  225 
2.10. 3H-Thymidine Proliferation Assay.  226 
Th1 and Th2 cell lines were plated on anti-CD3/CD28-coated wells (100,000 - 125,000 227 
cells/well) and treated with CMP5 inhibitor, or vehicle control (DMSO) and/or increasing 228 
concentrations of IL-2 at the indicated concentrations. Two days after treatment, cells were 229 
pulsed with 1 µCi of tritiated-thymidine (3H-thymidine). After 18 hours, cells were harvested on 230 
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a Filtermate196 harvester (Packard/Perkin-Elmer, Waltham, MA, USA) and the amount of 231 
amount of 3H-thymidine incorporated into the DNA was measured in a TopCount microplate 232 
scintillation and luminescence counter (Packard/Perkin-Elmer). 233 
2.11. Intracellular flow cytometry.  234 
On collection day, cells were treated with PMA/ionomycin and GolgiStop (BD Biosciences) for 235 
4-6 hours and washed with FACS buffer prior to Fc region blockade and surface antibody 236 
staining (10 minutes, 4°C). Samples were then fixed with Fixation/Permeabilization buffer and 237 
washed with Permeabilization/Wash buffer (buffers from BD Biosciences, Cat# 554715). 238 
Intracellular proteins T-bet (Biolegend 644807), IL-17 (Biolegend 506916), and RORgt 239 
(eBiosciences 12-698880) were stained with the corresponding antibodies (T-bet clone: 4B10,  240 
IL-17 clone: TC11-18H10.1) and RORgt clone: AFKJS-9) for 30 minutes at 4 degrees. 241 
CD4+CD44+ T cells were gated on to analyze the Tbet+RORgt+, IL-17+RORgt+, and Tbet+IL-17+ 242 
double-positive populations.  243 
2.12. shRNA lentivirus transfection and transduction.  244 
Lentiviral vectors expressing five different PRMT5-targeted shRNAs (target set RHS4533-245 
EG10419) and the universal negative control, pLKO.1 (RHS4080) were acquired from Open 246 
Biosystems.  HEK293T cells (Takara Clontech) were transfected with lentiviral vectors plus 247 
DNA vectors encoding HIV Gag/Pol and VSV-G in 10cm dishes with Lipofectamine 2000 (Life 248 
Technologies), according to manufacturers instructions. Lentiviral particle-containing 249 
supernatant was collected after 72 hours, filtered through 0.45µm filters, and concentrated using 250 
ultracentrifugation in a Sorvall SW-41 swinging bucket rotor. Human Th1 cells were prepared by 251 
resuspending 500,000 cells in 50µl concentrated lentivirus plus 8µg/ml polybrene. Human Th1 252 
cells were transduced by spinoculation at 2000xg for 2 hours at room temperature and then 253 
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incubated for 1hr at 37 degrees. Virus was then washed out and cells were plated on anti-254 
CD3/CD28 coated plates for proliferation or protein. 255 
2.13. siRNA tranfection with Neon electroporation.  256 
To knockdown PRMT5, we selected three siRNAs targeting different areas in the PRMT5 gene. 257 
Two siRNAs (namely, si#1 (5’-AAT TCC AAG GTG CAA TAG CGG CCT GTC TC-3), si#2 258 
(5’-ACA CUU CAU AUG UCU GAG A-3’) were synthesized in-house with the Silencer siRNA 259 
construction kit (Thermofisher AM1620M). The third siRNA (si#3) was purchased from Ambion 260 
(Cat # s77695). To transfect T cells, we used the Neon transfection system (Invitrogen) 261 
electroporation, following manufacturer’s instructions and adapting them as indicated below. 262 
Human Th cells were prepared by washing twice with phosphate-buffered saline (PBS), 263 
removing all of the supernatant after the last wash. Five million primary T cells were 264 
ressuspended in 100µl of T buffer containing 1.5µg of siRNA and electroporated (1 pulse at 265 
2100V for 20ms) using the Neon 100µl transfection pipette. Cells were mixed 1:1 with 100µl of 266 
2% Viability Buffer (gift from Dr. Renzhi Han at OSU) to promote cell viability after 267 
electroporation. Finally, cells were plated into media lacking penicillin/streptomycin. 268 
Proliferation and protein expression were monitored as indicated in the text.  269 
2.14. OVA-induced Delayed Type Hypersensitivity.  270 
Complete Freund’s Adjuvant (CFA) (Difco) and ovalbumin (OVA) emulsion was prepared at a 271 
1:1 v/v ratio for a final concentration of 1500µg OVA per ml PBS. BALB/c mice were injected 272 
with 100µl of emulsion in both the dorsal proximal scruff and base of tail (150µg of OVA per 273 
mouse). Control groups included non-immunized mice and immunized mice that are not 274 
subsequently challenged with OVA. One week after immunization, aggregated OVA was 275 
prepared by suspending in PBS at a concentration of 10mg/ml in a 15ml tube. Solution was 276 
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heated in 80ºC water bath for 60 minutes. Mice were then challenged with 300µg of aggregated 277 
OVA, by injecting 30µl of solution into the left footpad of immunized mice. After an additional 278 
week, mice were re-challenged in the same manner. (Non-immunized mice were also challenged 279 
at this step.) 24 hours after the second challenge, mice were euthanized by CO2 asphyxiation and 280 
cervical dislocation. Each footpad of the mice was measured using calipers for swelling and 281 
weighed for changes in mass. Additionally, spleens were taken and processed for in vitro studies 282 
as indicated.  283 
2.15. Experimental Autoimmune Encephalomyelitis.  284 
For induced EAE (Fig. 7A-I), either Hooke Reagent or Myelin Oligodendrocyte Glycoprotein 285 
(MOG) (CSBio) and Complete Freund’s Adjuvant (CFA) (Difco) emulsion was prepared. 286 
CFA/MOG emulsion was prepared in a 1:1 v/v ratio for a final concentration of 1000µg MOG 287 
per ml PBS. C57/B6 mice (Taconic) received 100µl of emulsion subcutaneously in the dorsal 288 
proximal scruff and base of the tail. About 2 hours after immunization, mice were injected 289 
intraperitoneally with 100µl of 2ng/µl pertussis toxin. 24 hours later, mice were injected again 290 
with 100µl of 2ng/µl pertussis toxin. Mice were monitored for disease every day and treated with 291 
25mg/kg HLCL65 or DMSO vehicle control as indicated. At indicated timepoints, mice were 292 
euthanized by injection with 20mg/ml ketamine/4mg/ml xylazine (120µl per 20g mouse) and 293 
perfused with phosphate-buffered saline (PBS). Spleens, brains and spinal cords were collected 294 
from representative mice and processed for in vitro studies as indicated. To isolate brain and 295 
spinal cord mononuclear cells, brains and spinal cords were processed through a 70µm strainer 296 
and separated by a 70%-30% isotonic percoll gradient.  297 
For spontaneous EAE (Fig. 7J-L), three MBP TCR Tg mice that developed EAE spontaneously 298 
(scores=1.5-2) were euthanized by CO2 asphyxiation and cervical dislocation. Splenocytes were 299 
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isolated and activated with 2µg/ml MBPAc1-11 for 48 hours in the presence of PRMT5 300 
inhibitors or vehicle control. Tbet, IL-17, and RORgt expression were analyzed by intracellular 301 
flow cytometry.  302 
 303 
  304 
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3. Results 305 
3.1. PRMT5 protein is up-regulated upon memory T cell reactivation. 306 
PRMT5 is over-expressed in several lymphoid malignancies, where it promotes uncontrolled cell 307 
growth and survival of transformed cells (35). However, its role in non-malignant memory T cell  308 
proliferative responses is unknown. After exposure to their cognate antigen, previously 309 
sensitized T cells activate a signaling cascade that enhances metabolic activity and drives 310 
maximum proliferation 2-3 days post activation. Subsequently, the proliferative rate of T cells 311 
gradually decreases, and cells that survive the contraction period return to a non-proliferative 312 
resting state 7 days after activation (21). In order to determine whether PRMT5 plays a role in 313 
this process, PRMT5 expression was analyzed by Western blotting at various time-points after 314 
Myelin Basic Protein Ac1-11 (MBP)-specific T cell receptor (TCR) transgenic mouse memory 315 
Th1 or Th2 cells (characterized in Supplemental Fig. 1) were restimulated with immobilized 316 
anti-CD3/CD28. Compared to resting memory T cells, PRMT5 was up-regulated 2.5 fold in Th1 317 
cells and 2.4  fold in Th2 cells at the 48 hour timepoint, the peak of PRMT5 expression (Fig. 1A, 318 
B). PRMT5 was subsequently down-regulated at day four, reaching baseline levels by day seven. 319 
These results led us to hypothesize that PRMT5 promotes proliferation during the normal cycle 320 
of T cell activation.  321 
 322 
3.2. Selective PRMT5 inhibition blunts TCR-mediated memory T cell expansion. 323 
To determine if PRMT5 activity is required for memory T cell proliferation, resting memory Th1 324 
and Th2 T cells were activated in vitro and the extent of T cell expansion was measured by 325 
tritiated (3H) thymidine incorporation assay in the presence of the previously described PRMT5 326 
inhibitor, Compound 5 (CMP5) (51), or DMSO vehicle control. CMP5 was designed to 327 
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selectively and reversibly bind within the PRMT5 active site to prevent transfer of the methyl 328 
group from donor S-adenosyl methionine, SAM, to the arginine substrate-binding pocket. CMP5 329 
selectively inhibits PRMT5-mediated symmetric dimethylation but not other PRMTs (51). 330 
Overall, these data indicate that CMP5 is a selective PRMT5 inhibitor. CMP5 treatment of mTh1 331 
and mTh2 cells strongly inhibited T cell proliferation (Fig. 1C, E). A detailed analysis of 332 
apoptosis status via Annexin V / PI staining revealed that there were no significant differences in 333 
apoptotic or dead cells in cells treated with PRMT5 inhibitor (Fig 1D, F), indicating that the 334 
reduced proliferation could not be explained by cell death. Interestingly, we noticed a small but 335 
significant difference in Th1 vs. Th2 suppression with CMP5. Th1 cell proliferation was more 336 
sensitive to PRMT5 inhibitors than Th2 cell proliferation (Th1: 95.4% inhibition; Th2: 90.5% 337 
inhibition, t test, p<0.005). To further explore this phenomenon, we analyzed the inhibitory 338 
concentration (IC)50 values to PRMT5 inhibitor CMP5 for both cell types. Indeed, we confirmed 339 
that CMP5 more potently inhibited Th1 cell proliferation (IC50 = 3.7 µM) than Th2 cell 340 
proliferation (IC50 = 9.2 µM) (Fig 1G, Table 1). To determine if this phenomenon was isolated 341 
or if it would replicate with CMP5 derivatives, we treated cells with a second-generation 342 
bioavailable PRMT5-selective inhibitor, HLCL65 (Supplemental Fig. 2A, B). HLCL65 343 
selectively inhibited PRMT5-mediated symmetric dimethylation (Supplemental Fig. 2C, D). 344 
HLCL65 inhibited T cell proliferation more potently than CMP5, but also suppressed Th1 cells 345 
(IC50 = 1.1 µM) more effectively than Th2 cells (IC50 = 4.0 µM) (Fig. 1H, Table 1). Overall, 346 
these data indicate that PRMT5 promotes murine memory T cell expansion and that 347 
inflammatory memory Th1 cells are more sensitive to targeting with PRMT5 inhibitors than Th2 348 
cells. To determine whether the proliferation or differentiation of newly activated naïve T cells 349 
was similarly dependent on PRMT5 activity, we treated freshly isolated naïve CD4+ T cells with 350 
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PRMT5 inhibitors. Both CMP5 and HLCL65 suppressed T cell proliferation in a dose-dependent 351 
manner (Supplemental Fig. 3A, B). Interestingly, and reminiscent of Th2 cells behavior, naïve 352 
CD4+ T cells were more resistant than memory Th1 cells to PRMT5 inhibitors (Supplemental 353 
Fig. 3A, B). We also observed decreased IFN-g in supernatants from naive T cell cultures 354 
differentiated with CMP5 and HLCL65 in the absence of exogenous polarizing signals 355 
(Supplemental Fig. 3C,D). Overall, these results show preferential suppressive effects of 356 
PRMT5 inhibitors on memory Th1 responses that drive inflammatory autoimmune diseases such 357 
as MS.  358 
 359 
3.3. PRMT5 is essential for human T cell activation and expansion. 360 
Targeting of pathogenic Th cell expansion may be beneficial as a therapy in human Th1 361 
mediated autoimmune diseases. To determine whether PRMT5 plays a similar role in human T 362 
cells, we restimulated previously differentiated human memory Th1- and Th2-enriched cells 363 
from healthy donors (characterized in Supplemental Fig. 4) and analyzed PRMT5 expression by 364 
Western blot from 0-7 days. We found that, similar to mouse T cells, PRMT5 was upregulated 365 
2.1 fold in Th1 cells and 1.9 fold in Th2 cells by 48 hours post-activation (Fig. 2A, B). PRMT5 366 
was then downregulated to resting levels by 7 days post-activation. Importantly, PRMT5 was 367 
also essential for the expansion of human T cells. The PRMT5-selective inhibitor, CMP5, 368 
preferentially suppressed human Th1 over Th2 cell proliferation (Th1: 43% inhibition, Th2: 9% 369 
inhibition, p < 0.05), (Fig. 2C, E) but had minimal effects on cell death (Fig. 2D, F). To further 370 
evaluate the increased sensitivity of Th1 over Th2 cells to PRMT5 inhibition, we calculated the 371 
IC50 of human T cells when treated with CMP5 (Th1 IC50 = 26.9 µM vs Th2 IC50 = 31.6 µM) and 372 
HLCL65 (Th1 IC50 = 5.7 µM vs Th2 IC50 = 14.3 µM) (Fig. 2G, H, Table 1). To genetically 373 
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validate a role for PRMT5 in proliferation, we knocked down PRMT5 expression via shRNA 374 
lentiviral transduction in human Th1 cells. PRMT5 shRNA partially reduced PRMT5 protein 375 
levels (45%) but not other PRMTs (1 and 7) and significantly decreased Th1 cell proliferation 376 
(Fig. 3A). Although significant, the mild suppression of proliferation could be explained by the 377 
low lentiviral transduction efficiency expected in primary T cells, coupled to the proliferative 378 
advantage of untransduced, i.e. PRMT5-sufficient, cells. To increase efficiency, we used the 379 
Neon Transfection System, which provided 70-90% transfection efficiency in our primary 380 
human Th1/2 cell lines (Figure 3B). Electroporation with either of three PRMT5-specific 381 
siRNAs efficiently suppressed human Th1 and Th2 cell proliferation to a degree that correlated 382 
with PRMT5 knockdown (Fig. 3C-D). These results validate a role for PRMT5 in T cell 383 
proliferative responses. Interestingly, we observed that PRMT5 siRNA transfection was 384 
accompanied by PRMT1 protein suppression, particularly in Th2 cells (Fig. 3C-D) cells. Since 385 
the three siRNAs target different areas in PRMT5 and all of them were confirmed to lack 386 
complementarity with PRMT1, it is unlikely that this is a direct effect of the siRNAs on PRMT1 387 
but rather an indirect effect via PRMT5. Further studies should aim to elucidate the significance 388 
of this finding. Overall, these data indicate that PRMT5 is functionally conserved in both mouse 389 
and human T cells and plays a critical role in memory Th cell reactivation and expansion.   390 
 391 
3.4. PRMT5 expression is dependent upon TCR-induced NF-κB signaling. 392 
The NF-κB pathway has been associated with PRMT5 in hematologic malignancies (56) but the 393 
pathways involved in PRMT5 expression in T cells are unknown. T cell reactivation activates 394 
several signaling pathways, including the NF-κB pathway, leading to IL-2 production and 395 
proliferation. NF-κB transcription factors are kept inactive in the cytoplasm through binding to 396 
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the inhibitory Iκ-B subunits. Upon T cell activation, the Iκ-B subunit is phosphorylated by IKKa 397 
and proteasomally degraded, allowing nuclear translocation of NF-κB and activation of 398 
transcription (57). To test whether NF-κB played a role in the up-regulation of PRMT5 399 
expression after TCR/CD28 costimulation, we treated human Th cells with the IKK-α inhibitor 400 
Bay11-7082 (henceforth referred to as Bay11) during the first 8 hours of activation. After 48 401 
hours of TCR/CD28 stimulation, we observed a decrease in PRMT5 protein levels in healthy 402 
human donor Th1 cells treated with Bay11 (Fig. 4A). In contrast, PRMT5 expression in Th2 403 
cells was less dependent on NF-κB signaling than Th1 cells, as evidenced by stable levels of 404 
PRMT5 expression treated with Bay11 (Fig. 4B). There were no differences in cell death with 405 
Bay11 treatment (Fig. 4C, D), indicating that the changes in protein expression observed could 406 
not be explained by cell death. As expected (58), NF-κB inhibition also resulted in a 65% 407 
reduction of downstream cytokine IL-2 levels in Th1 cells (Fig. 4E). These data are consistent 408 
with NF-κB signaling promoting PRMT5 expression and IL-2 secretion during TCR-mediated 409 
activation of Th1 and Th2 cells. 410 
 411 
3.5. PRMT5 inhibition suppresses IL-2 secretion and IL-2 restoration rescues T cell 412 












proliferation	observed	with	PRMT5	inhibition	in	Th1	cells.	To test if the blunted T cell 424 
proliferation observed after PRMT5 inhibition could be rescued with IL-2 supplementation, 425 
memory Th1 cells were activated with anti-CD3/CD28 in the presence or absence of PRMT5 426 
inhibitor and with increasing amounts of exogenous IL-2. Doses from 1 to 20 ng/ml were chosen 427 
since it was calculated that at least 10 ng/ml would be needed to restore the supernatant IL-2 428 
levels observed in the vehicle Th1 condition (as in Fig 5A).  T cell proliferation was evaluated 429 
through tritiated thymidine incorporation assay. Treatment with 25µM CMP5 inhibited mouse 430 
Th1 cell proliferation by 91% (t test p<0.001) (Fig 5C). As expected, addition of IL-2 enhanced 431 
proliferation in the vehicle condition, reaching a peak at 5 ng/ml. Addition of IL-2 in the 432 
presence of PRMT5 inhibitor increased proliferation in a dose-dependent manner, reaching 433 
100% of the control values at 10 ng/ml (Fig 5C). Similarly, treatment with  25µM CMP5 434 
suppressed human Th1 cell proliferation by 50%, and addition of exogenous IL-2 rescued 435 
proliferation (Fig. 5D). The recovery of Th1 T cell proliferation with exogenous IL-2 indicates 436 
that IL-2 pathways are active downstream of IL-2R and supports the notion that inhibition of IL-437 
2 secretion by PRMT5 inhibitors contributes to the observed reduction in Th1 T cell 438 
proliferation. However additional mechanisms may also play a role in PRMT5 inhibitor-439 
mediated suppression of proliferation, particularly in Th2 cells. 440 
 441 
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3.6. PRMT5 inhibition suppresses in vivo OVA-induced, delayed-type hypersensitivity 442 
inflammatory responses.   443 
The effectiveness of PRMT5 inhibitors at suppressing inflammatory memory T cell responses 444 
suggested they may be beneficial in inflammatory or autoimmune disease. To test this, we used 445 
the ovalbumin (OVA)-induced delayed type hypersensitivity (DTH) mouse model and HLCL65, 446 
a more potent and bioavailable derivative of CMP5 (Fig.1H, 2H, Supplemental Fig. 2). First, 447 
we analyzed PRMT5 expression in the spleen after ovalbumin (OVA) immunization with 448 
Complete Freund’s Adjuvant (CFA). We observed that 10 days post immunization, PRMT5 449 
expression was significantly upregulated in the spleen (Fig. 6A), suggesting that PRMT5 450 
expression is relevant to in vivo DTH immune responses.  In the DTH model (outlined in Fig. 451 
6B), ovalbumin (OVA) immunization with Complete Freund’s Adjuvant (CFA) induces OVA-452 
specific T cell response that causes footpad inflammation in mice upon subsequent exposure to 453 
adjuvant-free OVA and memory CD4+ T cell expansion. HLCL65 treatment during the re-454 
challenge period reduced footpad swelling by 40% (p < 0.05), a measure of inflammation (Fig. 455 
6C). In addition, compared to vehicle, HLCL65 treatment reduced OVA-specific T cell 456 
proliferation by 36%  (Fig. 6D) and IFN-g production by 70% (Fig. 6E). These data indicate that 457 
our novel PRMT5 inhibitor HLCL65 suppresses T cell mediated responses and inflammation in 458 
vivo. 459 
 460 
3.7. Prophylactic or therapeutic treatment with HLCL65 ameliorates Experimental 461 
Autoimmune Encephalomyelitis (EAE).  462 
The ability of PRMT5 inhibitors to suppress in vivo inflammatory T cell responses could be 463 
beneficial in the autoimmune disease MS. We saw that PRMT5 was up-regulated in the spleen at 464 
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5 and 10 days after immunization with CFA/MOG (Fig. 7A), suggesting that PRMT5 plays an 465 
important role in the immune response against myelin antigens in vivo. In the myelin 466 
oligodendrocyte glycoprotein (MOG)-induced murine EAE model, T cell responses against this 467 
myelin antigen result in ascending paralysis. We first tested whether short-term prophylactic 468 
HLCL65 treatment (5 days 25mg/kg every other day starting at immunization) could prevent 469 
EAE. Indeed, HLCL65-treatment resulted in delayed disease onset (16.9 days for HLCL65-470 
treated mice vs. 13.4 days for vehicle treated mice) and a 33% reduction in disease incidence, 471 
compared to vehicle-treated mice (Table 2). Importantly, HLCL65-treated mice presented 472 
reduced EAE disease burden, as measured by Area Under the Curve (AUC), compared to vehicle 473 
control (AUC HLCL65 vs. vehicle:  8.2 vs. 2.1, p = 0.016) (Fig. 7B, Table 2). These clinical 474 
effects were associated with reduced MOG-specific T cell proliferative responses (Fig. 7C), 475 
reduced CNS IL-17 production (Fig. 7D), and suppressed Tbet mRNA expression in the CNS 476 
(Fig. 7E). With these promising results, we tested HLCL65 during a therapeutically relevant 477 
window for MS patients, i.e., after clinical signs had developed. HLCL65 treatment, beginning at 478 
14 days post-immunization (average score at treatment initiation = 2.7 out of 5), suppressed 479 
existing EAE clinical signs as measured by the total disease burden (AUC HLCL65 vs. vehicle: 480 
19.1 ± 1.6 vs 27.31 ± 3.1, Fig. 7F, Table 3).  This disease suppression correlated with a 481 
reduction in MOG-specific T cell proliferation of HLCL65-treated mice (Fig. 7G). Additionally, 482 
inflammatory Th1 and Th17 responses were diminished in HLCL65-treated mice (Fig. 7H, I). 483 
These data further support that PRMT5 activity may be essential for T cell function, and our 484 
novel PRMT5-selective inhibitors effectively suppress T cell-mediated inflammation. Next, to 485 
test whether PRMT5 inhibitors could suppress preformed encephalitogenic Th17 cells, 486 
splenocytes from MBP TCR Tg that had spontaneously developed EAE (average score = 1.7) 487 
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were activated with antigen in the presence or absence of CMP5 and HLCL65. CMP5 treatment 488 
significantly suppressed IL-17+RORgt+ (Fig. 7J) Th17 cells and, particularly, a pathogenic T-489 
bet+RORgt+ population(61) (Fig. 7K) in a dose-dependent manner. A similar dose-dependent 490 
decrease in pathogenic T-bet+IL-17+ Th17 cell population(62) was apparent, but did not reach 491 
statitistical significance (Fig. 7J-L). Similar results were observed with HLCL65 treatment (data 492 
not shown). Taken together, these results indicate that PRMT5 promotes pathogenic Th1 and 493 
Th17 cell responses that promote inflammation and autoimmunity.   494 
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4. Discussion 495 
Memory T cell reactivation after antigen exposure rapidly induces T cell proliferation and 496 
effector function. This process can be beneficial, as in vaccination immunity, or deleterious, as in 497 
perpetuation of pathogenic responses in autoimmunity. Here, we show by expression knockdown 498 
and pharmacologic means that PRMT5, a methyltransferase that catalyzes symmetric 499 
dimethylation of arginine residues in histones and other proteins, promotes the activation and 500 
expansion of memory Th lymphocytes following antigen re-exposure.  501 
 502 
The first indications of a key role for arginine methylation in lymphocyte activation originated 503 
from conditions and treatments that inhibit all SAM-dependent methylation reactions (25,	26). 504 
PRMTs have been proposed to mediate some of these effects (29), but the role of individual 505 
PRMTs in these processes remained unresolved. We found that antigen re-exposure in memory T 506 
cells up-regulates PRMT5 expression as T cells proliferate and expand, followed by a 507 
contraction phase in which PRMT5 expression is progressively lost. The temporal link between 508 
PRMT5 expression and proliferation, together with the observed inhibition of proliferation upon 509 
selective PRMT5 inhibition, indicates that PRMT5 activity is necessary for TCR engagement-510 
induced memory T cell expansion. Th2 cell expansion was less dependent on PRMT5 activity 511 
than that of Th1 cells. This difference was reproduced in both mouse and human Th cells, 512 
indicating that this is a conserved difference that may impact human disease. However, 513 
differential sensitivity to PRMT5 inhibition did not appear to stem from differences in PRMT5 514 
expression, which was equivalent in Th1 and Th2 cells. It is possible that PRMT5 activity is 515 
lower in Th2 than Th1 cells due to expression of type I methyltransferases, which compete for 516 
substrates with PRMT5 (63). This difference offers the intriguing possibility that targeting 517 
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PRMT5 may modulate the Th1/Th2 balance defect observed in autoimmune/inflammatory 518 
diseaseas such as Multiple Sclerosis (12,	13).  519 
 520 
The exact chain of events that leads to PRMT5 up-regulation in T cells is unclear. A link 521 
between the NF-kB pathway leading to activation of the repressive p65/HDAC/Sp1 complex and 522 
loss of PRMT5 targeting miRNA has been reported in mantle cell lymphoma (64). We had also 523 
previously found that NF-kB inhibition suppresses PRMT5 expression in EBV-transformed cells 524 
(51). Since TCR engagement activates the NF-kB pathway in T cells, a similar mechanism may 525 
regulate PRMT5 expression in T cells. Indeed, blocking NF-kB signaling attenuated, but did not 526 
completely erase, PRMT5 expression in human Th1, but not Th2, cells. This indicates that while 527 
NF-kB is an important driver of PRMT5 expression in Th1 cells, other TCR-induced pathways 528 
play a more significant role in regulating PRMT5 expression, especially in Th2 cells. TCR 529 
signaling cascades include the NFAT, Erk1/2, p38 and JNK MAPK. Interestingly, inhibitors of 530 
the p38 and JNK-MAPK, but not ERK1/2, pathway have been shown to inhibit hypoxia-induced 531 
up-regulation of PRMT5 in lung epithelial cells (65). While future studies will be required to 532 
clarify the extent to which these pathways affect PRMT5 up-regulation in T cells, NF-kB 533 
appears to play a major role in TCR-induced PRMT5 expression in human Th1, but not Th2, 534 
cells. Additionally, several studies have shown that PRMT5 activates NF-kB signaling through 535 
arginine methylation of p65 (56,	66-68), suggesting that the NF-kB-PRMT5 signaling axis 536 
could involve a positive feedback loop. Additional studies are required to validate this feedback 537 
loop and evaluate its role in T cells.  538 
 539 
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Several pathways downstream of TCR activation converge on activation of the IL-2 promoter to 540 
induce T cell proliferation (18,	19,	69). Here, we found that IL-2 secretion is dependent on 541 
PRMT5 activity and that exogenous IL-2 addition to PRMT5 inhibitor-treated cells restored 542 
proliferation in Th1 cells. A role for PRMT5 in IL-2 production is consistent with the 543 
observations by Richard et al that PRMT5 siRNA suppresses IL-2 secretion in the Jurkat cancer 544 
T cell line (59). This effect is thought to be mediated by PRMT5-catalyzed arginine methylation 545 
on histones. In support of this hypothesis, symmetrically dimethylated proteins associate to the 546 
IL-2 promoter after T cell activation. In contrast, PRMT5 did not directly associate with the IL-2 547 
promoter. These data are consistent with PRMT5 indirectly regulating IL-2 expression, via SDM 548 
of target proteins. Although the specific proteins that are methylated and bind to the IL-2 549 
promoter remain to be defined, two proteins that form an IL-2 promoter-binding complex, 550 
namely NF-45 and NF-90, have been proposed as candidate targets(59). Another candidate is the 551 
TCR signaling protein Vav-1, whose SDM has been reported to promote IL-2 expression (70). 552 
Overall, our data point to IL-2 as one of the mechanisms by which PRMT5 regulates 553 
proliferation in Th1 cells. However, since we observe only a 60% reduction in IL-2 production 554 
yet T cell proliferation is reduced by 90-95% when treated with CMP5, it is likely that PRMT5 555 
regulates proliferation by several mechanisms. As Th2 cells do not secrete large amounts of IL-2, 556 
further studies are required to determine the mechanism by which PRMT5 promotes Th2 cell 557 
proliferation. 558 
 559 
Memory T cell responses play a critical role in chronic T cell-mediated diseases such as 560 
autoimmunity and allergy (71,	72). For example, increased memory T cells have been found in 561 
MS patients with active disease and further increase during disease flare (4), while the memory 562 
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to naïve T cell ratio diminishes in patients responding to therapy (73). Importantly, inhibition of 563 
methyltransferases successfully suppresses T cell activation and established clinical EAE and 564 
other inflammatory/autoimmune diseases (25-28) but the lack of selectivity has so far prevented 565 
the development of these treatments as a therapy. Our data indicates that selective PRMT5 566 
inhibition reproduces the suppression of memory T cell expansion observed with pan-567 
methyltransferase inhibitors and may be similarly effective in autoimmunity. Indeed, in vivo 568 
treatment with PRMT5 inhibitors was able to suppress two models of inflammatory/autoimmune 569 
disease, i.e., DTH footpad inflammation and EAE Central Nervous System (CNS) inflammation. 570 
PRMT5 inhibitors were effective at suppressing clinically established EAE disease. While a 571 
contribution of PRMT5 inhibition in non-T cells, i.e. CNS cells or antigen-presenting cells 572 
(APCs), to EAE suppression cannot be ruled out, our data is consistent with T cell being a major 573 
target. Effects on APCs could result on reduced TcR engagement and T cell responses. However, 574 
in vitro experiments showed similar suppressive effects when T cells are activated by anti-575 
CD3/CD28 (Fig. 1E) or antigen-loaded APCs (Fig. 1C). In addition, EAE HLCL65 treatment 576 
suppressed previously generated T cell responses that are less dependent on APC costimulation. 577 
The similarity in suppression of proliferation and inflammatory cytokines from in vitro and in 578 
vivo DTH/EAE studies is also consistent with T cells being a major target. To investigate 579 
relevance to human disease, we analyzed genome-wide association studies from the International 580 
Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium. 581 
Interestingly, rs4410871 was identified as a high frequency SNP in the MYC locus in multiple 582 
sclerosis patients (74). MYC has been shown to be upregulated after T cell activation (75) and 583 
also, to promote PRMT5 expression (37,	38). Taken together, these data suggest that PRMT5 584 
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Figures and Figure Legends. 892 
 893 
Figure 1. Proliferating murine Th1 and Th2 T cells express increased PRMT5 protein 894 
levels. (A-B) Myelin Basic ProteinAc1-11 (MBP)-specific T cell receptor (TCR) transgenic (tg) 895 
memory Th1 (A) and Th2 (B) cells were lysed at resting, 1, 2, 3, 4 or 7 days after anti-896 
CD3/CD28 stimulation and analyzed for PRMT5 protein expression by Western blotting. 897 
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Resting cells were non-proliferating T cells and were collected 7-10 days after activation of the 898 
Th cell line with MBPAc1-11	and irradiated splenocytes. b-actin was used as a loading control. 899 
Relative intensity quantification data is shown above a representative blot and was determined 900 
by normalizing PRMT5 expression to b-actin expression using ImageStudio. Data is 901 
representative of 3-4 independent experiments (n=5 for experiment shown). (One-way ANOVA 902 
followed by Sidak's multiple comparison-adjusted t test). (C-F) MBP-TCR Tg memory Th1(C-903 
D) and Th2 (E-F) cells were stimulated with MBPAc1-11	for	48	hours	in the presence of the 904 
PRMT5 inhibitor CMP5 or vehicle control (DMSO) and proliferation (C, E) and viability (D, F) 905 
were measured by 3H-thymidine incorporation or Annexin V staining, respectively. (Student’s t 906 
test). Data representative of 3-4 experiments (shown experiment n=4). L: live; EA: early 907 
apoptotic, LA: late apoptotic, N: necrotic, D: dead. Data pooled from 2 independent experiments 908 
(n=4). (G-H) MBP-TCR Tg memory Th1 and Th2 cells were stimulated with anti-CD3/CD28 909 
for 48 hours in the presence of various concentrations of PRMT5 inhibitors CMP5 (G), HLCL65 910 
(H), or vehicle control. Proliferation was monitored via 3H-thymidine incorporation. (Two-way 911 
ANOVA followed by Sidak’s multiple comparison adjusted t test). Data representative of 3-4 912 










Figure 2. PRMT5 is essential for human Th1 and Th2 cell expansion. Human CD4+ T cells 922 
were isolated from whole blood and differentiated in the presence of Th1- or Th2- inducing 923 
conditions. (A-B) After differentiation, Th1 (A) and Th2 (B) cells were reactivated on anti-924 
CD3/CD28 and cells were lysed at resting, 1, 2, 3, 4 and 7 days. PRMT5 protein expression was 925 
analyzed by Western blotting and b-actin was used as a loading control.  Relative intensity 926 
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quantification data is shown above a representative blot. Data is representative of 3 independent 927 
experiments (n=3 for experiment shown). (One-way ANOVA followed by Sidak's multiple 928 
comparison-adjusted t test).  (C-F) Human memory Th1 (C, D) and Th2 (E, F) T cells were 929 
activated with anti-CD3/CD28 for 48 hours in the presence of the PRMT5 inhibitor CMP5 or 930 
vehicle control (DMSO) and the extent of T cell expansion (C, E) or viability (D, F) was 931 
measured by 3H-thymidine incorporation or Trypan blue exclusion, respectively. (Student’s t 932 
test). Data representative of 3-4 experiments (shown experiment n=3). (G-H) Human memory 933 
Th1 and Th2 cells were activated, as in C-F, in the presence of varying concentrations of vehicle 934 
control, CMP5 (G), or HLCL65 (H) and T cell proliferation was measured by 3H-thymidine 935 
incorporation. (Two-way ANOVA followed by Sidak’s multiple comparison adjusted t test). * 936 















Figure 3. PRMT5 knockdown suppresses human T cell proliferation.  951 
A. Human memory Th1 cells were activated with anti-CD3/CD28 for 48 hours in the presence of 952 
PRMT5 short hairpin RNA or scrambled (scr) control and proliferation was monitored via 3H-953 
thymidine incorporation. Left panel shows proliferation, relative to the scrambled control 954 
condition (data pooled from 3 independent experiments, Student’s t test, n=8). Right panels show 955 
PRMT5, PRMT1 and PRMT7 expression measured by Western blot and quantified using 956 
ImageStudio software. (B-D) Human Th1 and Th2 cells were activated as in A in the presence of 957 
a Cy3-labeled NS siRNA, nonsense siRNA control (NS) or three different PRMT5-specific 958 
siRNAs (si#1-3). (B) Cy3siRNA+ cells (gated on CD4+ cells) were quantified by flow cytometry 959 
as a measure of transfection efficiency. The tranfection efficiency shown corresponds to Th1 960 
cells.  Equivalent efficiency was observed in Th2 cells. (C-D) Proliferation of human Th1 (C) 961 
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and Th2 (D) cells was  monitored by 3H-thymidine incorporation and expressed as a relative 962 
proliferation ratio to proliferation in the NS tranfection control condition. PRMT5 and PRMT1 963 
protein expression was measured by Western blot and quantified using ImageStudio Software 964 
(One-way ANOVA followed by Sidak's multiple comparison-adjusted t test). Protein data is 965 
representative of three independent experiments. Proliferation data is pooled from three 966 
independent experiments (shown n=9).  * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, n.s. 967 







Figure 4. T cell activation drives PRMT5 expression in an NF-κB-dependent manner. 974 
Differentiated human Th1 (A) or Th2 (B) cells were reactivated on anti-CD3/CD28, treated with 975 
DMSO vehicle or increasing amounts of the NF-kB pathway inhibitor Bay11-7082 for 8 hrs. 976 
Cells were lysed for Western blot analysis of PRMT5 expression 48 hours after initial activation. 977 
b-actin was used as a loading control.  Relative intensity quantification data is shown above a 978 
representative blot quantified with ImageStudio. Data is representative of 3 independent 979 
experiments (n=3 for experiment shown). (One-way ANOVA followed by Sidak's multiple 980 
comparison-adjusted t test). (C-D) Differentiated human Th1 (C) and Th2 (D) cells were treated 981 
as described in A-B and viability was monitored by Trypan blue exclusion. (Two-way ANOVA 982 
followed by Sidak’s multiple comparison-adjusted t test). Data was pooled from 3 independent 983 
experiments (n=6).  (E) Differentiated human Th1 cells were treated as described in A and 984 
supernatants were collected to analyze the concentration of IL-2 production by ELISA. Data 985 





Figure 5. PRMT5 inhibition suppresses IL-2 production and exogenous IL-2 rescues 990 
CMP5-inhibited Th cell proliferation. (A) IL-2 measured by an Enzyme Linked 991 
Immunosorbent Assay (ELISA) in supernatants of murine MBP TCR Th1 memory T cells (A) or 992 
human Th1 cells (B) stimulated through the TCR at various time-points in the presence of CMP5 993 
or vehicle control. Th2 cells not shown since they do not secrete IL-2. (Student’s t test). Data 994 
from 2-3 independent experiments (n=4). (C-D) Proliferation at 48 hours, measured by 3H-995 
thymidine incorporation, of mouse memory MBP TCR tg Th1 (C) or human memory Th1 (D) T 996 
cells activated with anti-CD3/CD28 in the presence of CMP5 or vehicle control and increasing 997 
amounts of exogenous IL-2 (ng/ml). (ANOVA followed by Sidak's multiple comparison-998 
adjusted t test). Data representative of 2-3 independent experiments (shown experiment n=3). * 999 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, n.s. =not significant 1000 
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 1001 
Figure 6. PRMT5 inhibition suppresses T cell responses and inflammation in the Delayed-1002 
Type Hypersensitivity model.  1003 
(A) PRMT5 expression in mouse spleens from naïve mice and 5 or 10 days after immunization 1004 
with Ovalbumin (OVA) and Complete Freund’s Adjuvant (CFA). Spleens	were	crushed	under	1005 
liquid	nitrogen	and	lysed	for	Western	blot	analysis	using	β-actin	as	a	loading	control.	Data	1006 
representative	of	2	independent	experiments	(data	shown	n=3) (B) Schematic of delayed-1007 
type hypersensitivity (DTH) model and treatment strategy. Mice were sensitized to OVA with 1008 
Complete Freund’s Adjuvant (CFA)/OVA immunization (flanks and tail base). 7 and 14 days 1009 
later, mice were footpad challenged with OVA and daily treated intraperitoneally with 25mg/kg 1010 
PRMT5 inhibitor HLCL65 or DMSO between day 7 and 14. (C) Inflammation was evaluated on 1011 
day 15 after initial sensitization using calipers to quantify footpad swelling. (D) Day 15 1012 
splenocytes were activated in the presence or absence of OVA for 72 hours and proliferation was 1013 
monitored by 3H-thymidine incorporation. (E) Supernatants were collected from splenocytes 1014 
isolated as described in C, and interferon-gamma production was measured by ELISA. (n=8). 1015 
Data representative of 2 independent experiments.  1016 
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 1017 
Figure 7. PRMT5 inhibition suppresses in vivo inflammatory T cell responses and clinical 1018 
disease in the Experimental Autoimmune Encephalomyelitis (EAE) murine model of 1019 
Multiple Sclerosis. 	1020 
 48 
(A) PRMT5 expression in mouse spleens from naïve mice, 5 or 10 days after immunization with 1021 
CFA/Myelin Oligodendrocyte Glycoprotein (MOG) in the preclinical EAE phase. Spleens were 1022 
crushed under liquid nitrogen and lysed for Western blot analysis using β-actin as a loading 1023 
control. Representative data of 2 independent experiments (n=4).  (B) Clinical EAE score in 1024 
mice preventatively treated with DMSO vehicle or 25mg/kg HLCL65 (q.o.d., arrows indicate 1025 
treatment) from days 0-9 after CFA/MOG immunization to induce EAE (n=10). EAE score (B) 1026 
and day of onset were blindly monitored daily. (C-D) Splenocytes (C) and brain/spinal cord 1027 
mononuclear cells (D) were isolated from DMSO or HLCL65-treated mice and activated in the 1028 
presence or absence of MOG 35-55. MOG-specific proliferation (C) was monitored via 3H-1029 
thymidine incorporation (One-way ANOVA followed by Sidak’s multiple comparison adjusted t 1030 
test, n=3). MOG-specific IL-17 production (D) was measured by ELISA (Student’s t test, n=2 1031 
samples each pooled from 6 individual mice/group). (E) RNA was isolated from brains and 1032 
spinal cord homogenates of DMSO or HLCL65-treated mice and Tbx21 mRNA expression was 1033 
measured by qRT-PCR (Student’s t test, n=6). (F) EAE in mice treated with DMSO vehicle or 1034 
25mg/kg HLCL65 (q.o.d., arrows indicate treatment) starting on day 14 post-immunization, after 1035 
EAE developed. Mice were randomly assigned to either group (pre-treatment average score were 1036 
1.92 for DMSO and 1.96 for HLCL65 group) and blindly scored for EAE daily. (n=6-7). (G-I) 1037 
Mice were CFA/MOG immunized and treated with DMSO or 25mg/kg HLCL65 every other day 1038 
starting 1 week after immunization. Splenocytes were isolated from DMSO or HLCL65-treated 1039 
mice 10 days after immunization and activated in the presence or absence of MOG. MOG-1040 
specific proliferation was monitored via 3H-thymidine incorporation (G), IFNγ+-secreting cells 1041 
were quantified by flow cytometry (gated on CD4+, CD44+ cells) (H), and IL-17 production was 1042 
measured by ELISA (I). (One-Way ANOVA followed by Sidak’s multiple comparison-adjusted 1043 
t test). (J-L) Splenocytes were isolated from MBP TCR Tg mice with spontaneous EAE,  1044 
activated with MBPAc1-11 in the presence of with the indicated concentrations of PRMT5 1045 
inhibitors CMP5 and HLCL65, or DMSO vehicle control for 48hrs. Frequencies of RORgt+Tbet+ 1046 
(J), RORgt+IL-17+ (K), and IL-17+Tbet+ (L) T cells were quantified by intracellular flow 1047 





Supplemental Figure 1. 1052 
 1053 
Supplemental Figure 1. Characterization of Myelin Basic Protein (MBP) Ac1-11 TcR 1054 
transgenic (Tg) Th1 and Th2 cell lines.  1055 
IFN-g and T-bet (A) and IL-4 and GATA-3 (B) flow cytometry analysis of MBP TcR Tg Th1 1056 
and Th2 cell lines activated for 48 hours with anti-CD3/CD28. Cells were treated with transport 1057 
inhibitor GolgiPlug for the last four hours of culture. The percentage of cytokine positive cells 1058 
from A and B is quantified in C (IFN-g+ cells) and D (IL-4+ cells). Flow data was from one 1059 
experiment (n=3) representative of three independent experiments. The amount of secreted IFN-g 1060 
(E) and IL-4 (F) was quantified by ELISA on supernatants from MBP TcR Tg Th1 and Th2 cell 1061 
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lines activated on anti-CD3/CD28 for 48 hours. ELISA data is from one experiment (n=3) 1062 
representative of three independent experiments. 1063 
 1064 
Supplemental Figure 2. Characterization of Second Generation PRMT5 inhibitor, 1065 
HLCL65.  1066 
(A) Chemical structure of HLCL65. (B) The PRMT5 binding pocket is shown as cartoon (PDB 1067 
4GQB), α-helix, β-sheets and turns are colored pink, yellow and grey, respectively. The bound 1068 
SAM analog (A9145C) is shown in orange, and the H4 peptide with substrate residue Arg3 is 1069 
shown in cyan as lines. Docked HLCL65 molecule is represented by sticks in green. 1070 
 (C) Histone methyltransferase assays were performed by incubating H1-depleted HeLa-core 1071 
histones (2 µg) with affinity-purified hSWI/SNF associated Fl-PRMT5, or Fl-PRMT7 in the 1072 
presence of [3H]AdoMet and control DMSO or 20uM of HLCL65.  Reaction samples were 1073 
spotted onto Whatman P-81 filter paper before methylation of histone was quantified by liquid 1074 
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scintillation counting. Each reaction was done in triplicate. (D) CCMCL1 cell lines were treated 1075 
with 20uM of HLCL65, 20 uM of Epizyme compound for 24h or 48h, and RIPA extracts (40 µg) 1076 
were analyzed for Symm-H3(Me2)R8 or asymm-H3(Me2)R8 protein levels. Actin was used as 1077 
loading control. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 1078 
 1079 
 1080 
Supplemental Figure 3. PRMT5 inhibitors suppress naïve T cell proliferation less potently 1081 
than inflammatory memory Th1 cell responses.  1082 
(A-D) Naïve CD4+ T cells were isolated from splenocytes, activated on anti-CD3/CD28 and 1083 
treated in the presence of DMSO vehicle control, CMP5 (A, C), or HLCL65 (B, D). At 48 hours, 1084 
proliferation was monitored by 3H-thymidine incorporation (A-B) and IFNg production was 1085 
quantified by ELISA (C-D).  1086 
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 1087 
Supplemental Figure 4. Characterization of Human Th1- and Th2-enriched Cells.  1088 
The amount of production of  IFN-g (A) and IL-4 (B) was quantified by ELISA of the 1089 
supernatants from normal donor human Th1- and Th2-enriched cells activated for 24 hours with 1090 
anti-CD3/CD28. Data is representative of three independent experiments (n=2). 1091 
  1092 
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Tables 1093 
  Cell Type IC50 (uM)  Hill Slope R-squared 
CMP5 
mTh1 3.7 -0.8334 0.96 
mTh2 9.2 -3.174 0.98 
hTh1 26.9 -3.454 0.94 
hTh2 31.6 -6.276 0.96 
HLCL65 
mTh1 1.1 -1.392 0.91 
mTh2 4 -2.321 0.97 
hTh1 5.7 -3.291 0.98 
hTh2 14.3 -4.15 0.97 
 1094 
Table 1. IC50 values for PRMT5 inhibitors CMP5 and HLCL65 in mouse and human Th1 1095 
and Th2 cells.   1096 
IC50, Hill Slope, and R2 values reported for PRMT5 inhibitors in Th1 and Th2 cell lines.  1097 
 1098 
  DMSO HLCL65 Change from DMSO p-value 
EAE incidence (%) 90 57 -33% N/A 
Disease Onset (Days) 13.44 ± 0.53 16.86 ± 0.96 +3.42 days 0.0053 
Area under the Curve (AUC) 8.214 ± 1.58 2.143 ± 1.41 -6.071 0.0159 
Average Score D17 2.3 ± 0.37 1.0 ± 0.48 -1.3 0.048 
Average Max Score 2.45 ± 0.37 1.0 ± 0.48 -1.45 0.0285 
n 10 7 n/a n/a 
 1099 
Table 2. Prophylactic treatment with HLCL65 ameliorates EAE.  1100 
Mean ± standard deviation for characteristics of EAE in mice treated with DMSO or HLCL65 in 1101 




  DMSO HLCL65 
Change from 
DMSO p-value 
EAE Incidence (%): pre Tx 100 100 0 N/A 
Disease Onset (Days): pre Tx 11.67 ± 0.49 12.43 ± 0.37 +0.76 days n.s.  
Average Score D14* 2.7 ± 0.40 2.7 ± 0.40 0 n.s.  
Area Under the Curve (AUC): pre Tx 4.60 ± 1.15 3.91 ± 0.91 -0.69 n.s.  
Area Under the Curve (AUC): post Tx 27.31 ± 3.13 19.11 ± 1.61 -8.2 0.0329 
Average Max Score: pre Tx 2.7 ± 0.40 2.7 ± 0.40 0 n.s.  
Average Max Score: post Tx 3.88 ± 0.38 2.93 ± 0.44 -0.95 0.0535 
Average Score D22 3.5 ± 0.51 2.14 ± 0.19 -1.36 0.0228 
n 6 7 n/a n/a 
 1105 
Table 3. Therapeutic treatment with HLCL65 ameliorates EAE.  1106 
Mean ± standard deviation for characteristics of EAE in mice treated with DMSO or HLCL65 in 1107 
a therapeutic model. Tx = treatment. *Treatment initiation occurred on day 14.  1108 
 1109 
